10 Best Performing Stocks of Q1 2026 to Watch for Q2
This article highlights Alumis Inc. (NASDAQ:ALMS) as one of the best-performing stocks of Q1 2026, with a 145.87% performance. Raymond James and Guggenheim both reiterated "Buy" ratings following positive Phase 3 trial data for its drug "envu" for plaque psoriasis, which showed a strong safety profile advantage over a competitor. The article, which is part of a larger list, also suggests that while ALMS has potential, certain AI stocks might offer greater returns and less downside risk.
10 Best Performing Stocks of Q1 2026 to Watch for Q2
This article highlights Alumis Inc. (NASDAQ:ALMS) as one of the top-performing stocks of Q1 2026, with a 145.87% performance. Raymond James and Guggenheim both reiterated "Strong Buy" and "Buy" ratings, respectively, following positive Phase 3 trial data for its plaque psoriasis drug, envu, which showed a strong safety profile compared to a competitor. The article, however, suggests that some AI stocks might offer greater return potential and lower downside risk than ALMS.
Foresite entities move ALUMIS (ALMS) shares in pro rata in-kind distributions
Foresite Labs Affiliates 2021, LLC and Foresite Labs, LLC reported Form 4 transactions for ALUMIS (ALMS) common stock on April 1, 2026. These transactions, coded "J," represent pro rata, in-kind distributions among affiliated Foresite entities and are not market purchases or sales. The filings clarify that these internal transfers occurred without additional consideration, falling under Exchange Act exemptions 16a-13 and 16a-9, and involved a total of 4,103,630 shares.
Alumis (ALMS) insider-linked entities shift 4.1M shares via in-kind distributions
Alumis (ALMS) director and 10% owner James B. Tananbaum reported an internal restructuring of 4,103,630 shares of common stock. These were "J" transactions, meaning pro rata, in-kind distributions among affiliated entities (Foresite and Labs-related funds and LLCs) for no consideration, not open-market purchases or sales. Tananbaum disclaims beneficial ownership beyond his pecuniary interest and group status.
Why Alumis (ALMS) Is Down 8.4% After Positive Phase 3 Psoriasis Data And FDA Filing Plans
Alumis Inc. reported positive Phase 3 results for envudeucitinib in psoriasis, leading to plans for an FDA New Drug Application in mid-2026. Despite the strong clinical data and potential for envudeucitinib to anchor Alumis' immunology pipeline, the stock saw a decline, possibly due to over-optimistic valuation and existing risks such as the company being loss-making and relying on equity issuance. The situation highlights a tension between scientific strengthening and heightened investor expectations.
Why Alumis (ALMS) Is Down 8.4% After Positive Phase 3 Psoriasis Data And FDA Filing Plans
Alumis Inc. recently announced positive Phase 3 results for envudeucitinib in moderate-to-severe plaque psoriasis, demonstrating strong skin clearance and safety. Despite these positive results and plans for a New Drug Application filing in late 2026, the company's stock, ALMS, is down 8.4%. The article explores how this data and the planned FDA submission impact Alumis' investment narrative, highlighting both opportunities and risks, such as the company's loss-making status and reliance on equity issuance.
Why Alumis Inc. Shares Are Suddenly Surging
Alumis Inc. (ALMS) shares are experiencing a significant surge due to strong Phase 3 data for its oral psoriasis drug, envudeucitinib, which demonstrated competitive efficacy and a superior safety profile. This positive news, coupled with notable insider buying and growing optimism for a 2026 regulatory submission, has led analysts like Oppenheimer to raise price targets and reiterate "outperform" ratings. The stock's year-to-date performance is up 125.72%, with a current market cap of $2.8 billion.
Why Alumis Inc. Shares Are Suddenly Surging
Alumis Inc. (ALMS) shares surged after the company unveiled strong Phase 3 results for its oral psoriasis drug, envudeucitinib, at the 2026 American Academy of Dermatology Annual Meeting. The positive trial data, showing solid skin clearance and symptom relief, has led to increased investor enthusiasm and analysts raising their price targets, including Oppenheimer setting a new target of $55. This clinical success is reshaping Wall Street's outlook on the stock, with the company planning to file for U.S. approval later this year.
Alumis (NASDAQ:ALMS) Trading 12.1% Higher Following Analyst Upgrade
Alumis (NASDAQ:ALMS) shares surged 12.1% after Oppenheimer raised its price target from $50 to $55, maintaining an outperform rating. Insider buying also contributed to positive sentiment, with significant purchases reported by Foresite Capital and director James B. Tananbaum. Despite mixed analyst sentiment and weak fundamentals, the average rating remains a "Moderate Buy" with an average target price of $38.60.
Analysts Are Bullish on These Healthcare Stocks: Alumis Inc. (ALMS), Aquestive Therapeutics (AQST)
Analysts have expressed bullish sentiment towards healthcare stocks Alumis Inc. (ALMS) and Aquestive Therapeutics (AQST). Chardan Capital and Morgan Stanley maintained Buy ratings for Alumis Inc., with price targets around $38, representing a significant upside. Lake Street also maintained a Buy rating for Aquestive Therapeutics, setting a price target of $6.00, contributing to a Strong Buy consensus for both companies.
Alumis Furthers Its Case In TYK2 Race With Phase III Envudeucitinib Data
Alumis has advanced its TYK2 inhibitor, envudeucitinib, with positive Phase III clinical trial data for plaque psoriasis. This development positions Alumis as a significant contender in the competitive market for autoimmune treatments, particularly those targeting IL-23 and IL-17 pathways. The news highlights ongoing progress in therapies for chronic immune-mediated diseases.
Alumis (ALMS) Maintains "Buy" Rating and Price Target by Chardan Capital | ALMS Stock News
Chardan Capital has reiterated its "Buy" rating for Alumis (ALMS), maintaining a price target of $38.00. This decision aligns with previous analyst evaluations, including Morgan Stanley and Raymond James, who also assigned positive ratings with similar or higher price targets. Alumis Inc. is a biopharmaceutical company focusing on TYK2 inhibitors for various inflammatory and neurodegenerative diseases.
Alumis (Nasdaq:ALMS) - Stock Analysis
This report provides a stock analysis for Alumis Inc. (ALMS), a clinical-stage biopharmaceutical company focusing on autoimmune disorders. It highlights that ALMS is currently undervalued by analysts with a projected 42.6% discount to fair value, despite being unprofitable, and forecasting revenue growth of 57.86% per year. The company's stock has shown high volatility and substantial dilution in the past year, but has exceeded the US Pharmaceuticals industry and the overall US Market in shareholder returns over the past year.
Alumis (NASDAQ:ALMS) Trading Down 11.5% on Analyst Downgrade
Alumis Inc. (NASDAQ:ALMS) shares dropped by 11.5% in mid-day trading after HC Wainwright lowered its price target on the stock from $40.00 to $25.00, while maintaining a buy rating. The company recently missed analyst estimates for both earnings per share and revenue in its latest quarterly report, showing a negative return on equity and net margin. Despite the downgrade, several institutions and insiders have recently increased their stakes in Alumis, with insiders now owning 40.7% of the company.
Alumis: Envudeucitinib Shows Robust PASI 90/100 Responses and QoL Gains in Phase 3 ONWARD Trials
Alumis reported positive Phase 3 ONWARD trial results for envudeucitinib, showing high skin-clearance rates (PASI 90 and PASI 100) and significant improvements in quality of life (QoL) and itch for psoriasis patients. The drug demonstrated progressive deepening of response through Week 24, including impressive outcomes for scalp psoriasis, with a safety profile consistent with Phase 2 studies.
Alumis Inc. Soars On Breakthrough Psoriasis Drug Update
Alumis Inc. (ALMS) shares are experiencing volatility and are jumping after the company unveiled strong Phase 3 trial results for its oral psoriasis drug, envudeucitinib, at the American Academy of Dermatology meeting. The data showed better skin clearance and a solid safety profile versus current treatments. This positive update has led several Wall Street analysts to raise their price targets on Alumis Inc. stock, indicating growing confidence in the drug's commercial potential ahead of a planned 2026 regulatory filing.
Phase 3 win positions Alumis (NASDAQ: ALMS) psoriasis pill for 2026 NDA
Alumis Inc. announced positive Phase 3 results for its oral TYK2 inhibitor, envudeucitinib, in treating moderate-to-severe plaque psoriasis, showing high rates of skin clearance and improved quality of life. The trials indicated a favorable safety profile, consistent with previous Phase 2 data. Alumis plans to submit a New Drug Application in the second half of 2026, with concurrent development in systemic lupus erythematosus.
Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout
Alumis presented positive Phase III data for its oral TYK2 inhibitor, envudeucitinib (ESK‑001), in moderate-to-severe plaque psoriasis, demonstrating strong efficacy, rapid onset, and favorable safety. The company plans to file a New Drug Application (NDA) and expects Phase IIb lupus trial results in Q3, while also considering global commercialization partnerships. Key opinion leaders expressed enthusiasm for the "maximally inhibiting TYK2" approach, highlighting significant improvements in PASI scores, itch reduction, and quality of life.
Alumis’ Envudeucitinib Meets Co-Primary Endpoints in ONWARD1 and ONWARD2 Phase 3 Trials
Alumis Inc. announced positive results from its global phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib, an oral TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis. The trials demonstrated significant improvements in skin clearance, symptom burden, and quality of life, meeting co-primary endpoints. Envudeucitinib also showed rapid and substantial efficacy in difficult-to-treat areas like the scalp and exhibited a favorable safety profile, positioning it as a potential leading oral therapy for psoriasis.
ALUMIS INC. P3 trial data spotlights TYK2 inhibitor potential in oral psoriasis therapy
ALUMIS INC. has announced positive late-breaking Phase 3 clinical data for its investigational TYK2 inhibitor, positioning it as a potential leading oral therapy for psoriasis. The company will share further details and regulatory plans during an investor webcast on March 29 at 5pm MDT. These results highlight the drug's strong potential in the competitive psoriasis treatment market.
Psoriasis pill eased itch by Week 2, deepened skin clearance by Week 24
Alumis (ALMS) reported positive Phase 3 results for its oral TYK2 inhibitor, envudeucitinib, for moderate-to-severe plaque psoriasis, showing rapid and deep skin clearance and symptom relief. The drug achieved significant PASI 90 and PASI 100 responses by Week 24, with early improvements in itch and quality of life. Alumis plans to submit a New Drug Application (NDA) in the second half of 2026.
Alumis (ALMS) price target increased by 11.20% to 40.35
This article reports that the price target for Alumis (ALMS) has been increased by 11.20% to $40.35. No further details are provided regarding the reasons for this change or the source of the price target.
Taking a Page From Cancer Drugs, Autoimmune Biotech Alumis Aims for Precision Immunology
Alumis, an autoimmune biotech company, is applying a precision medicine approach, similar to cancer drug development, to immunology. Their lead drug, envudeucitinib, a TYK2 inhibitor, has shown promising Phase 3 results for plaque psoriasis, achieving high skin clearance rates. The company aims to differentiate its drug through superior efficacy and plans to expand its application to other autoimmune conditions like lupus and potentially neurological disorders, emphasizing tailoring treatments to individual patient needs.
Alumis Inc. (NASDAQ:ALMS) Given Average Recommendation of "Moderate Buy" by Analysts
Alumis Inc. has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $39.60. Despite missing Q1 earnings and revenue estimates, the company has seen significant insider buying, with the Director and Foresite Labs acquiring substantial shares. Several research firms have issued "buy" or "overweight" ratings, indicating confidence in the stock's future performance.
Alumis (NasdaqGS:ALMS) Stock Forecast & Analyst Predictions
Alumis Inc. (NasdaqGS:ALMS) is forecast to grow earnings and revenue by 22.9% and 57.9% per annum respectively, with EPS expected to increase by 32.9% annually. Despite this growth, the company is projected to remain unprofitable over the next three years, with a forecast return on equity of -91% in three years. Analysts have provided updated estimates, including recent increases in consensus revenue estimates and some decreases in EPS estimates, alongside various company news regarding clinical trials, equity offerings, and acquisitions.
Alumis Inc. (ALMS) Receives a Buy from Morgan Stanley
Morgan Stanley maintained a Buy rating on Alumis Inc. (ALMS) with a price target of $38.00. This positive outlook is supported by a 5-star analyst, Terence Flynn, and positive corporate insider sentiment, indicating increased insider buying. The company recently reported a quarterly revenue of $2.07 million and a GAAP net loss of $110.75 million.
Alumis (ALMS) Q4 Loss Of US$92.9 Million Tests Bullish Growth Narrative
Alumis (ALMS) reported a Q4 loss of US$92.9 million and a full-year net loss of US$243.3 million, despite revenue growth to US$24.1 million. Analysts forecast significant revenue growth of 57.9% per year but expect the company to remain unprofitable for at least three more years. The stock currently trades at a P/B of 10.4x with an implied upside of 57.2%, which tests the bullish growth narrative against substantial ongoing losses and valuation concerns.
Alumis (ALMS) Q4 Loss Of US$92.9 Million Tests Bullish Growth Narrative
Alumis (ALMS) reported a Q4 net loss of US$92.9 million and a full-year loss of US$243.3 million despite US$24.1 million in trailing revenue. Analysts forecast 57.9% annual revenue growth but also project at least three more years of unprofitability, challenging the bullish narrative centered on future scale rather than current margins. The company trades at a P/B of 10.4x, higher than the industry average but lower than peers, with analysts seeing 57.2% potential upside despite ongoing losses and dilution.
Alumis (ALMS) Sees Price Target Raised by Morgan Stanley | ALMS Stock News
Morgan Stanley has raised its price target for Alumis (ALMS) from $33.00 to $38.00, maintaining an "Overweight" rating. This increase reflects a positive outlook for the company, which is a clinical-stage biopharmaceutical firm focusing on autoimmune disorders. The average target price from 9 analysts is $39.00, implying a potential upside of 53.66% from its current price, with a consensus brokerage recommendation of "Buy."
Alumis (NASDAQ:ALMS) Given New $38.00 Price Target at Chardan Capital
Chardan Capital has raised its price target for Alumis (NASDAQ:ALMS) from $37.00 to $38.00, maintaining a "buy" rating, indicating a potential 49.72% upside. This comes despite recent weak earnings, as the company missed analyst expectations for Q4 EPS and revenue. Significant insider buying, totaling approximately $31 million in the last 90 days, shows strong internal confidence, with insiders now owning about 40.7% of the stock.
Alumis 2025 10-K: $24.05M revenue, $(2.86) EPS (loss)
Alumis reported a 2025 revenue of $24.05 million, mainly from a collaboration with Kaken. The company posted a net loss of $243.33 million, or $(2.86) per share, reflecting significant increases in R&D and G&A spending due to advancing late-stage programs and M&A activities. Strategic actions, including a public offering, extended its cash runway into early 2026.
[S-3ASR] ALUMIS INC. SEC Filing
Alumis Inc. has filed an S-3ASR shelf registration statement to allow for future offerings of various security types, including common stock, preferred stock, debt securities, and warrants. This filing enables ongoing capital market access, including a $300 million sales agreement for voting common stock with Cantor Fitzgerald & Co. The company is a clinical-stage biopharmaceutical firm focused on developing TYK2 inhibitors for immune-mediated diseases, with plans to submit a New Drug Application for envudeucitinib in PsO in late 2026.
Alumis (ALMS) details 2025 results, envudeucitinib NDA plan and cash raise
Alumis Inc. reported its full-year 2025 financial results, including total revenue of $24.05 million and a narrowed net loss of $243.33 million. The company highlighted positive Phase 3 results for envudeucitinib in plaque psoriasis, with plans for an NDA submission in the second half of 2026, and anticipated Phase 2b data for systemic lupus erythematosus in Q3 2026. A public offering in January 2026 raised $345.1 million, strengthening the company's financial position to advance its pipeline.
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
Alumis Inc. announced its financial results for the year ended December 31, 2025, highlighting positive Phase 3 topline results for envudeucitinib in moderate-to-severe plaque psoriasis and an anticipated NDA submission in 2H 2026. The company also reported plans for pivotal Phase 2b data for envudeucitinib in systemic lupus erythematosus in 3Q 2026 and discussed its TYK2 pipeline expansion strategy. Alumis raised $345.1 million in gross proceeds from a public offering in January 2026, extending its cash runway into the fourth quarter of 2027.
Alumis presents phase 3 psoriasis trial data at dermatology meeting By Investing.com
Alumis Inc. announced that Phase 3 ONWARD program data for envudeucitinib, an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis, will be presented at the 2026 American Academy of Dermatology Annual Meeting. The company also has a Phase 2b trial for systemic lupus erythematosus with topline data expected in Q3 2026. Despite being unprofitable, Alumis holds more cash than debt and has garnered positive analyst ratings and a successful public offering, with shares showing significant returns over the past year.
**Key Clinical Data to Be Revealed Soon** Biopharmaceutical company Alumis Inc. announced that the phase III clinical trial data of its lead candidate drug Envudeucitinib for the treatment of moderate-to-severe plaque psoriasis has been selected for the "Lat
Alumis Inc. announced that its lead drug candidate, Envudeucitinib, for plaque psoriasis, has been selected for a "Late-Breaking Breakthroughs" oral presentation at the 2026 AAD Annual Meeting. This oral TYK2 inhibitor shows promise for its efficacy and safety profile, targeting a large market with unmet medical needs. Positive phase III data could lead to a marketing application around the time of the meeting, significantly impacting Alumis's valuation and potentially attracting acquisition interest.
Experimental oral psoriasis drug’s Phase 3 results to debut at skin conference
Alumis Inc. announced that the Phase 3 ONWARD 1 and 2 results for its oral tyrosine kinase 2 (TYK2) inhibitor, envudeucitinib, for moderate-to-severe plaque psoriasis, will be presented at the 2026 American Academy of Dermatology Annual Meeting on March 28, 2026. A Phase 2 biomarker analysis from the STRIDE trial will also be presented as an e-poster. The company will host an investor webcast on March 29, 2026, to discuss the ONWARD data.
Alumis (NASDAQ:ALMS) Trading Down 3.5% - Here's What Happened
Alumis Inc. (NASDAQ:ALMS) shares dropped 3.5% on Tuesday, trading at $25.28 with significantly reduced volume compared to its average. Despite the intraday decline, analyst sentiment remains largely positive with a "Moderate Buy" consensus and price targets up to $46.00. Insider activity shows strong confidence, with key insiders and a major shareholder recently acquiring over 1.8 million shares worth approximately $31 million, raising insider ownership to about 40.7%.
ALMS Technical Analysis & Stock Price Forecast
This article provides a technical analysis for Alumis Inc (ALMS), indicating a "Buy" consensus based on various indicators. Key metrics include a MACD Buy signal, an RSI of 48.763 suggesting a neutral condition, and the stock trading above its 60-day and 200-day moving averages. The analysis identifies immediate resistance at $29.203 and strong support at $24.373.
Alumis Inc. (NASDAQ:ALMS) Sees Significant Drop in Short Interest
Alumis Inc. (NASDAQ:ALMS) experienced a 12.2% drop in short interest during February, with 7,953,241 shares short as of February 27th, representing approximately 12.8% of the company's shares. Major insiders, including Foresite Labs and Foresite Capital Management VI, acquired over 1.8 million shares worth about $31 million last quarter, increasing insider ownership to 40.7%. Analysts have a "Moderate Buy" consensus rating with a target price of $39, and several firms issued buy ratings with price targets up to $46.
Alumis Inc expected to post a loss of 98 cents a share - Earnings Preview
Alumis Inc (ALMS) is projected to report a loss of 98 cents per share, according to this earnings preview. The information was provided by Reuters and Refinitiv.
Alumis (NASDAQ:ALMS) Stock Price Down 6.7% - Should You Sell?
Alumis Inc. (NASDAQ:ALMS) experienced a 6.7% stock price drop on Wednesday, trading at $26.21 with significantly reduced volume. Despite the dip, analysts maintain a "Moderate Buy" rating with an average target price of $39, and company insiders, including Foresite entities, have recently increased their holdings, acquiring over 1.8 million shares in the past three months. The stock's current price remains above its 50-day and 200-day moving averages, suggesting underlying strength amidst the recent decline.
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Top Wall Street analysts have initiated coverage on four companies. Raymond James began coverage on Alumis Inc. with a Strong Buy rating and a $46 price target. B of A Securities initiated coverage on Ligand Pharmaceuticals Inc. with a Buy rating and a $244 price target. Oppenheimer also initiated coverage on Ocugen Inc. with an Outperform rating and a $10 price target. Cantor Fitzgerald initiated coverage on Satellos Bioscience Inc. with an Overweight rating.
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
This article highlights four new analyst initiations for Wednesday, March 11, 2026. B of A Securities initiated coverage on Ligand Pharmaceuticals (NASDAQ: LGND) with a Buy rating and a $244 price target. Other companies receiving new coverage include Alumis Inc. (NASDAQ: ALMS) with a Strong Buy, Satellos Bioscience Inc. (NASDAQ: MSLE) with an Overweight, and Ocugen Inc. (NASDAQ: OCGN) with an Outperform rating.
Raymond James initiates Alumis stock coverage citing psoriasis drug potential
Raymond James has initiated coverage on Alumis Inc (ALMS) with a Strong Buy rating and a $46.00 price target, anticipating ALMS's lead drug, envudeucitinib, to capture significant market share in psoriasis treatments due to its differentiated profile. This follows a successful upsized public offering and similar positive coverage from Stifel and Chardan Capital, all highlighting the drug's potential ahead of its New Drug Application submission in late 2026.
ALMS Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Alumis Inc. (ALMS), detailing its revenue breakdown, profitability margins, and a comparison with competitors like CNTA and CORT. Key financial indicators such as a 100.00% gross margin, but negative operating and net margins, are highlighted, alongside its market capitalization of $3.63 billion. The analysis aims to help evaluate ALMS's financial performance relative to its peers.
Alumis to Present at the Leerink Partners Global Healthcare Conference
Alumis Inc. (Nasdaq: ALMS) announced that its President and CEO, Martin Babler, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 10:40 a.m. ET. The company, a late-stage biopharma developing therapies for immune-mediated diseases, will stream the event live on its website, with a replay available for 90 days.
Alumis to Present at the Leerink Partners Global Healthcare Conference
Alumis Inc. will present at the Leerink Partners Global Healthcare Conference on March 9, 2026. Martin Babler, President and CEO, will participate in a fireside chat to discuss the company's progress as a late-stage biopharma company developing targeted therapies for immune-mediated diseases. A live webcast and a 90-day archive will be available on the Alumis website for those interested.
Alumis Inc. (NASDAQ:ALMS) Given Average Rating of "Moderate Buy" by Brokerages
Alumis Inc. (NASDAQ:ALMS) has received a consensus "Moderate Buy" rating from twelve brokerages, with an average one-year price target of $38.22. This comes alongside significant insider buying, including Foresite Labs and director Srinivas Akkaraju, who collectively purchased over 2.3 million shares totaling $35.5 million in the last 90 days. The company, focused on developing targeted therapies for immunological diseases, has shown strong stock momentum with its 50-day moving average significantly above its 200-day moving average.
ALMS SEC Filings - Alumis Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Alumis Inc. (ALMS) SEC filings, including annual 10-K, quarterly 10-Q, and material event 8-K reports. It highlights the use of AI-generated summaries to distill key information from these documents, focusing on financial statements, R&D, and pipeline developments for immune-mediated diseases. Investors can also track insider trading and public offerings, with real-time updates and AI support for understanding regulatory disclosures.
